Skip to content

Beta Bionics

US · BBNX #3406 by market cap Listed 2025
13.36 +0.04 +0.30%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.22 In line with history 47th percentile
5-year average 1.86 · #59 of 127 in Medical Devices
P/E ratio -10.74 In line with history 48th percentile
5-year average -10.78 · forward -7.99
P/S ratio 7.01 In line with history 36th percentile
5-year average 8.97 · forward 5.72 · #110 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Beta Bionics (BBNX) 726.34M -8.74 1.81 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value19.52 Economic moatNone UncertaintyVery High

Trading 46.1% below Morningstar's fair value estimate.

Fair value

Beta Bionics Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 16% discount to our quantitative fair value estimate of $19.52 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's solid growth strengthens our valuation estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth lies in the top 1% compared with global peers. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.

On a different note, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 18.0%, a core component of profitability, lies in the bottom 20% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Beta Bionics discussion 0 comments

Add a comment